SpectRx sells "non-core" SimpleChoice:
This article was originally published in Clinica
Executive Summary
In a move to further its cervical cancer treatment programme, SpectRx, of Norcross, Georgia, has announced that it is terminating the sales of all SimpleChoice products and has sold its SimpleChoice insulin pump product line to ICU Medical. "With the company focusing on developing its cervical cancer technology, insulin pumps were no longer core to that strategy," a SpectRx spokesperson told Clinica. SpectRx is currently working towards completing patient enrolment into its pivotal of its cervical cancer test, which aims to eliminate painful Pap and HPV samples and deliver immediate results. ICU, the San Clemente, California-based IV therapy specialist has acquired a majority of the assets of Sterling Medivations, the SpectRx subsidiary that developed SimpleChoice, for an undisclosed fee. ICU's purchase adds to its portfolio of insulin pumps, as it already manufactures and develops the Orbit 90 diabetes infusion set.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.